decreased by -8.4% YoY. 9M23 EBITDA increased by 4.2% YoY as a result of an improvement in core service revenue and well- controlled SG&A. The net profit closed at Bt22,084mn, surging 18% YoY driven by
Company’s authorized directors shall be empowered to consider, determine and modify other details which are necessary for and in relation to the allocation of the newly issued ordinary shares, including, but
person(s) designated by the Company’s authorized directors shall be empowered to consider, determine and modify other details which are necessary for and in relation to the allocation of the newly issued
Company’s authorized directors or any person(s) designated by the Company’s authorized directors shall be empowered to consider, determine and modify other details which are necessary for and in relation to
5th day of November 2008. (Mr. Vijit Supinit) Chairman Securities and Exchange Commission Remarks : The reason for issuing this Notification is that it deems appropriate to modify the qualifications of
. Notified this 5th day of November 2008. (Mr. Vijit Supinit) Chairman Securities and Exchange Commission Remarks: The reason for issuing this Notification is that it deems appropriate to modify the
manufacturing cosmeceuticals and modern medicine from FDA and controlled quality and operational efficiency which certified by international standards ISO 9001:2008, GMP, PICS, HACCP และ HALAL. Presently, At-Ze
located in Muang district, Chachoengsao province and authorized manufacturing cosmeceuticals and modern medicine from FDA and controlled quality and operational efficiency which certified by international
from FDA and controlled quality and operational efficiency which certified by international standards ISO 9001:2008, GMP, PICS, HACCP และ HALAL. Registered capital THB 50 million, divided into 500,000